Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Eslicarbazepine-acetate | hsa00030 | Pentose phosphate pathway | 1.08E-05 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Eslicarbazepine-acetate | hsa00040 | Pentose and glucuronate interconversions | 3.53E-02 | 1 | O60701 | UGDH | More | | Eslicarbazepine-acetate | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Eslicarbazepine-acetate | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Eslicarbazepine-acetate | hsa00220 | Arginine biosynthesis | 1.97E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | | Eslicarbazepine-acetate | hsa00250 | Alanine, aspartate and glutamate metabolism | 1.97E-02 | 2 | P49448, P15104 | GLUD2, GLUL | More | | Eslicarbazepine-acetate | hsa00500 | Starch and sucrose metabolism | 1.91E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Eslicarbazepine-acetate | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Eslicarbazepine-acetate | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Eslicarbazepine-acetate | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | Eslicarbazepine-acetate | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Eslicarbazepine-acetate | hsa00591 | Linoleic acid metabolism | 8.36E-04 | 1 | P11712 | CYP2C9 | More | | Eslicarbazepine-acetate | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.29E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Eslicarbazepine-acetate | hsa00670 | One carbon pool by folate | 3.15E-02 | 2 | O95954, Q99707 | FTCD, MTR | More | | Eslicarbazepine-acetate | hsa00730 | Thiamine metabolism | 1.55E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Eslicarbazepine-acetate | hsa00740 | Riboflavin metabolism | 3.53E-02 | 1 | P24666 | ACP1 | More | | Eslicarbazepine-acetate | hsa00830 | Retinol metabolism | 2.20E-02 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Eslicarbazepine-acetate | hsa00860 | Porphyrin and chlorophyll metabolism | 8.96E-04 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Eslicarbazepine-acetate | hsa00910 | Nitrogen metabolism | 1.97E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | | Eslicarbazepine-acetate | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.24E-03 | 3 | O95363, P14868, Q15046 | FARS2, DARS, KARS | More | | Eslicarbazepine-acetate | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Eslicarbazepine-acetate | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Eslicarbazepine-acetate | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Eslicarbazepine-acetate | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Eslicarbazepine-acetate | hsa01230 | Biosynthesis of amino acids | 2.22E-03 | 4 | P51854, P60891, Q99707, P37837 | TKTL1, PRPS1, MTR, TALDO1 | More | | Eslicarbazepine-acetate | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | | Eslicarbazepine-acetate | hsa01522 | Endocrine resistance | 3.41E-02 | 6 | P14780, P22694, Q9UM47, P08069, P10415, Q13323 | MMP9, PRKACB, NOTCH3, IGF1R, BCL2, BIK | More | | Eslicarbazepine-acetate | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Eslicarbazepine-acetate | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | Eslicarbazepine-acetate | hsa02010 | ABC transporters | 4.48E-02 | 1 | Q8IZY2 | ABCA7 | More | | Eslicarbazepine-acetate | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | Eslicarbazepine-acetate | hsa03013 | RNA transport | 1.57E-08 | 16 | O14980, P52298, Q09161, O14893, P61326, Q9H307, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, P23588, Q9Y6A5, Q06787, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, PNN, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, EIF4B, TACC3, FMR1, FXR1 | More | | Eslicarbazepine-acetate | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Eslicarbazepine-acetate | hsa03020 | RNA polymerase | 3.00E-02 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | | Eslicarbazepine-acetate | hsa03040 | Spliceosome | 3.35E-07 | 14 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Eslicarbazepine-acetate | hsa03060 | Protein export | 2.97E-03 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Eslicarbazepine-acetate | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Eslicarbazepine-acetate | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | | Eslicarbazepine-acetate | hsa04014 | Ras signaling pathway | 1.13E-02 | 9 | P42338, P20827, P49767, P08069, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, IGF1R, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Eslicarbazepine-acetate | hsa04015 | Rap1 signaling pathway | 5.95E-03 | 9 | P20827, P49767, P08069, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, IGF1R, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | Eslicarbazepine-acetate | hsa04024 | cAMP signaling pathway | 4.38E-02 | 4 | P42338, P0DP23, Q13370, Q13009 | PIK3CB, CALM1, PDE3B, TIAM1 | More | | Eslicarbazepine-acetate | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.57E-03 | 8 | Q8NHW4, P09341, P19875, P25024, P25025, P61073, Q13651, P14784 | CCL4L2, CXCL1, CXCL2, CXCR1, CXCR2, CXCR4, IL10RA, IL2RB | More | | Eslicarbazepine-acetate | hsa04062 | Chemokine signaling pathway | 5.65E-04 | 14 | P25024, P25025, P09341, P19875, P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | CXCR1, CXCR2, CXCL1, CXCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | | Eslicarbazepine-acetate | hsa04064 | NF-kappa B signaling pathway | 7.59E-13 | 26 | P10415, Q13489, P25963, P51617, O00463, Q13546, P14778, P01584, P01375, P19174, Q04759, Q9UDY8, Q13077, P67870, Q16548, P06239, Q8WV28, Q13315, P63279, P24522, Q8NHW4, P09341, P19875, Q06643, Q9UNE0, Q9NQC7 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, RIPK1, IL1R1, IL1B, TNF, PLCG1, PRKCQ, MALT1, TRAF1, CSNK2B, BCL2A1, LCK, BLNK, ATM, UBE2I, GADD45A, CCL4L2, CXCL1, CXCL2, LTB, EDAR, CYLD | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P22894 | MMP8 | Neutrophil collagenase | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.959 | P08246 | ELA2 | Neutrophil elastase | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.942 | P08235 | NR3C2 | Mineralocorticoid receptor | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.868 | P22894 | MMP8 | Neutrophil collagenase | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.765 | P08246 | ELA2 | Neutrophil elastase | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.716 | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | P22894 | MMP8 | Neutrophil collagenase | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | -0.744 | P08246 | ELA2 | Neutrophil elastase | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | -0.734 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.932 | P22894 | MMP8 | Neutrophil collagenase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.867 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P08246 | ELA2 | Neutrophil elastase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.814 | P08235 | NR3C2 | Mineralocorticoid receptor | Q13546 | RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | -0.749 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P01584 | IL1B | Interleukin-1 beta | 0.799 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | P01584 | IL1B | Interleukin-1 beta | 0.762 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P22894 | MMP8 | Neutrophil collagenase | P01375 | TNF | Tumor necrosis factor | 0.728 | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P22894 | MMP8 | Neutrophil collagenase | Q04759 | PRKCQ | Protein kinase C theta type | -0.756 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | P08235 | NR3C2 | Mineralocorticoid receptor | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.708 | P22894 | MMP8 | Neutrophil collagenase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.891 | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.796 | P22894 | MMP8 | Neutrophil collagenase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.806 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | P08246 | ELA2 | Neutrophil elastase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.725 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | P67870 | CSNK2B | Casein kinase II subunit beta | 0.709 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.958 | P22894 | MMP8 | Neutrophil collagenase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.843 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | P08246 | ELA2 | Neutrophil elastase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.766 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q8WV28 | BLNK | B-cell linker protein | -0.704 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | P08246 | ELA2 | Neutrophil elastase | Q13315 | ATM | Serine-protein kinase ATM | -0.742 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P63279 | UBE2I | SUMO-conjugating enzyme UBC9 | 0.756 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | P63279 | UBE2I | SUMO-conjugating enzyme UBC9 | 0.702 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.819 | P22894 | MMP8 | Neutrophil collagenase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.766 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P08246 | ELA2 | Neutrophil elastase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.7 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.727 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.727 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | Q13547 | HDAC1 | Histone deacetylase 1 | Q06643 | LTB | Lymphotoxin-beta | 0.74 | P08235 | NR3C2 | Mineralocorticoid receptor | Q9UNE0 | EDAR | Tumor necrosis factor receptor superfamily member EDAR | 0.819 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.799 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.825 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.763 |
| Eslicarbazepine-acetate | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | Eslicarbazepine-acetate | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Eslicarbazepine-acetate | hsa04070 | Phosphatidylinositol signaling system | 4.86E-02 | 3 | P0DP23, P42338, P27987 | CALM1, PIK3CB, ITPKB | More | | Eslicarbazepine-acetate | hsa04071 | Sphingolipid signaling pathway | 9.23E-06 | 7 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Eslicarbazepine-acetate | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Eslicarbazepine-acetate | hsa04080 | Neuroactive ligand-receptor interaction | 1.26E-04 | 10 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21462, P21730, Q16581, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, C3AR1, ADRB2 | More | | Eslicarbazepine-acetate | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | Eslicarbazepine-acetate | hsa04114 | Oocyte meiosis | 3.19E-03 | 5 | P51812, Q02750, P16298, Q17RY0, P08069 | RPS6KA3, MAP2K1, PPP3CB, CPEB4, IGF1R | More | | Eslicarbazepine-acetate | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Eslicarbazepine-acetate | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Eslicarbazepine-acetate | hsa04140 | Autophagy - animal | 6.54E-02 | 6 | P08069, P22694, Q14643, P10415, Q9H1Y0, Q04759 | IGF1R, PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Eslicarbazepine-acetate | hsa04142 | Lysosome | 1.46E-02 | 7 | P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | | Eslicarbazepine-acetate | hsa04144 | Endocytosis | 4.42E-05 | 11 | P0DMV8, Q9H444, O75351, Q9NZZ3, P62491, P42566, P61073, Q96B97, Q15438, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, CHMP5, RAB11A, EPS15, CXCR4, SH3KBP1, PSCD1, GIT2, SNX12 | More | | Eslicarbazepine-acetate | hsa04145 | Phagosome | 8.88E-04 | 9 | O75015, Q15080, P14598, Q13509, Q13488, P05164, O60603, P35443, P13765 | FCGR3B, NCF4, NCF1, TUBB3, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Eslicarbazepine-acetate | hsa04150 | mTOR signaling pathway | 7.74E-03 | 4 | P08069, Q02750, Q9NQL2, P51812 | IGF1R, MAP2K1, RRAGD, RPS6KA3 | More | | Eslicarbazepine-acetate | hsa04151 | PI3K-Akt signaling pathway | 4.77E-03 | 15 | P42338, P43657, P09603, P20827, P49767, Q9GZP0, P08238, Q8WYR1, P63218, P50151, P13612, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, CSF1, EFNA1, VEGFC, PDGFD, HSP90AB1, PIK3R5, GNG5, GNG10, ITGA4, CHAD, LAMB3, IL2RB, CCND3 | More | | Eslicarbazepine-acetate | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Eslicarbazepine-acetate | hsa04210 | Apoptosis | 1.52E-02 | 9 | Q13315, P10415, Q13489, P25963, P01375, P24522, Q16548, Q13077, Q14643 | ATM, BCL2, BIRC3, NFKBIA, TNF, GADD45A, BCL2A1, TRAF1, ITPR1 | More | | Eslicarbazepine-acetate | hsa04211 | Longevity regulating pathway | 1.34E-03 | 4 | Q12778, P08069, Q9UEF7, Q96KQ7 | FOXO1, IGF1R, KL, EHMT2 | More | | Eslicarbazepine-acetate | hsa04213 | Longevity regulating pathway - multiple species | 1.17E-04 | 8 | P42338, P08069, Q9Y4H2, Q08828, P51828, P0DMV8, P11142, Q13547 | PIK3CB, IGF1R, IRS2, ADCY1, ADCY7, HSPA1A, HSPA8, HDAC1 | More | | Eslicarbazepine-acetate | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Eslicarbazepine-acetate | hsa04217 | Necroptosis | 4.76E-04 | 9 | P01568, P23458, Q13489, Q9NQC7, Q13546, P0C0S5, Q9H444, Q9NZZ3, O75351 | IFNA21, JAK1, BIRC3, CYLD, RIPK1, H2AFZ, CHMP4B, CHMP5, VPS4B | More | | Eslicarbazepine-acetate | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | Eslicarbazepine-acetate | hsa04260 | Cardiac muscle contraction | 4.49E-02 | 3 | P67936, P13073, P12074 | TPM4, COX4I1, COX6A1 | More | | Eslicarbazepine-acetate | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Eslicarbazepine-acetate | hsa04270 | Vascular smooth muscle contraction | 5.83E-04 | 7 | P0DP23, P0DP24, Q08828, P51828, P35579, P35749, P35318 | CALM1, CALM2, ADCY1, ADCY7, MYH9, MYH11, ADM | More | | Eslicarbazepine-acetate | hsa04360 | Axon guidance | 2.47E-03 | 7 | P16333, P20827, O95631, P42338, P07332, P23528, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, CFL1, PLCG1 | More | | Eslicarbazepine-acetate | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Eslicarbazepine-acetate | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Eslicarbazepine-acetate | hsa04380 | Osteoclast differentiation | 9.58E-05 | 13 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, Q8N149, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, LILRA2, SIRPA | More | | Eslicarbazepine-acetate | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | Eslicarbazepine-acetate | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P08069 | IGF1R | More | | Eslicarbazepine-acetate | hsa04512 | ECM-receptor interaction | 4.41E-02 | 3 | Q13751, P13612, O15335 | LAMB3, ITGA4, CHAD | More | | Eslicarbazepine-acetate | hsa04520 | Adherens junction | 1.04E-03 | 3 | P37173, P08069, P24666 | TGFBR2, IGF1R, ACP1 | More | | Eslicarbazepine-acetate | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Eslicarbazepine-acetate | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | | Eslicarbazepine-acetate | hsa04610 | Complement and coagulation cascades | 1.14E-05 | 2 | P00734, P0C0L4 | F2, C4A | More | | Eslicarbazepine-acetate | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Eslicarbazepine-acetate | hsa04613 | Neutrophil extracellular trap formation | 3.78E-07 | 23 | P17252, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P0C0S5, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AFZ, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Eslicarbazepine-acetate | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | Eslicarbazepine-acetate | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | | Eslicarbazepine-acetate | hsa04621 | NOD-like receptor signaling pathway | 7.18E-04 | 13 | Q14643, P01568, P25963, Q13489, Q9H1Y0, P43490, O00463, P10415, Q13546, Q05823, P01375, P49913, P12838 | ITPR1, IFNA21, NFKBIA, BIRC3, ATG5, PBEF1, TRAF5, BCL2, RIPK1, RNASEL, TNF, CAMP, DEFA4 | More | | Eslicarbazepine-acetate | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Eslicarbazepine-acetate | hsa04623 | Cytosolic DNA-sensing pathway | 3.05E-06 | 4 | P01584, P01568, Q13546, Q8NHW4 | IL1B, IFNA21, RIPK1, CCL4L2 | More | | Eslicarbazepine-acetate | hsa04625 | C-type lectin receptor signaling pathway | 9.91E-04 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Eslicarbazepine-acetate | hsa04640 | Hematopoietic cell lineage | 4.59E-04 | 16 | P13612, P21926, P14778, P27930, P11215, P15144, P11836, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375, P01584 | ITGA4, CD9, IL1R1, IL1R2, ITGAM, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF, IL1B | More | | Eslicarbazepine-acetate | hsa04650 | Natural killer cell mediated cytotoxicity | 2.37E-07 | 17 | P16298, P50591, P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | | Eslicarbazepine-acetate | hsa04657 | IL-17 signaling pathway | 1.50E-05 | 9 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF, IL1B | More | | Eslicarbazepine-acetate | hsa04658 | Th1 and Th2 cell differentiation | 2.95E-05 | 14 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, P23458, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, JAK1, RUNX3 | More | | Eslicarbazepine-acetate | hsa04659 | Th17 cell differentiation | 1.70E-07 | 20 | P25963, Q04759, Q16539, P19174, P06239, P42224, P14784, P13765, P14778, P40189, Q9UL17, P23771, P84022, Q13485, P01584, P08238, P07766, P09693, P20963, P23458 | NFKBIA, PRKCQ, MAPK14, PLCG1, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, IL6ST, TBX21, GATA3, SMAD3, SMAD4, IL1B, HSP90AB1, CD3E, CD3G, CD247, JAK1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | -0.728 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P29375 | JARID1A | Lysine-specific demethylase 5A | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.764 | P29375 | JARID1A | Lysine-specific demethylase 5A | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.768 | Q13547 | HDAC1 | Histone deacetylase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.816 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.785 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.764 | P29375 | JARID1A | Lysine-specific demethylase 5A | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.83 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.872 | Q13547 | HDAC1 | Histone deacetylase 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.817 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.763 | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.769 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.721 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P29375 | JARID1A | Lysine-specific demethylase 5A | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.711 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.838 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 |
| Eslicarbazepine-acetate | hsa04660 | T cell receptor signaling pathway | 2.85E-05 | 17 | P01375, P25963, Q9UDY8, Q04759, P42338, P10747, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, NFKBIA, MALT1, PRKCQ, PIK3CB, CD28, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Eslicarbazepine-acetate | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Eslicarbazepine-acetate | hsa04664 | Fc epsilon RI signaling pathway | 2.40E-03 | 7 | P01375, Q16539, P42338, Q9UQC2, P07948, P19174, P09917 | TNF, MAPK14, PIK3CB, GAB2, LYN, PLCG1, ALOX5 | More | | Eslicarbazepine-acetate | hsa04666 | Fc gamma R-mediated phagocytosis | 2.97E-03 | 7 | O75015, P42338, P23528, P06396, O14494, P14598, P17252 | FCGR3B, PIK3CB, CFL1, GSN, PLPP1, NCF1, PRKCA | More | | Eslicarbazepine-acetate | hsa04668 | TNF signaling pathway | 2.13E-04 | 10 | P01375, O00463, Q13489, Q16539, P25963, P18848, P19875, P20749, Q13077, P14780 | TNF, TRAF5, BIRC3, MAPK14, NFKBIA, ATF4, CXCL2, BCL3, TRAF1, MMP9 | More | | Eslicarbazepine-acetate | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Eslicarbazepine-acetate | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Eslicarbazepine-acetate | hsa04724 | Glutamatergic synapse | 9.51E-03 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | | Eslicarbazepine-acetate | hsa04726 | Serotonergic synapse | 2.37E-02 | 2 | P31645, P11712 | SLC6A4, CYP2C9 | More | | Eslicarbazepine-acetate | hsa04727 | GABAergic synapse | 2.33E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | Eslicarbazepine-acetate | hsa04730 | Long-term depression | 1.34E-02 | 3 | Q14344, P08069, P07948 | GNA13, IGF1R, LYN | More | | Eslicarbazepine-acetate | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.66E-05 | 13 | P14778, P01584, Q08828, P51828, P22694, Q16539, P19174, P42338, Q14643, P24723, Q04759, P0DP24, P0DP23 | IL1R1, IL1B, ADCY1, ADCY7, PRKACB, MAPK14, PLCG1, PIK3CB, ITPR1, PRKCH, PRKCQ, CALM2, CALM1 | More | | Eslicarbazepine-acetate | hsa04912 | GnRH signaling pathway | 4.33E-02 | 6 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB | More | | Eslicarbazepine-acetate | hsa04913 | Ovarian steroidogenesis | 7.72E-03 | 3 | P42330, P22694, P08069 | AKR1C3, PRKACB, IGF1R | More | | Eslicarbazepine-acetate | hsa04914 | Progesterone-mediated oocyte maturation | 9.67E-04 | 7 | P08069, Q17RY0, P42338, Q13370, P08238, P51812, Q02750 | IGF1R, CPEB4, PIK3CB, PDE3B, HSP90AB1, RPS6KA3, MAP2K1 | More | | Eslicarbazepine-acetate | hsa04915 | Estrogen signaling pathway | 1.89E-03 | 6 | Q08828, P51828, P0DMV8, P0DP23, P0DP24, Q15788 | ADCY1, ADCY7, HSPA1A, CALM1, CALM2, NCOA1 | More | | Eslicarbazepine-acetate | hsa04920 | Adipocytokine signaling pathway | 4.49E-02 | 4 | P25963, P33121, Q04759, P01375 | NFKBIA, ACSL1, PRKCQ, TNF | More | | Eslicarbazepine-acetate | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Eslicarbazepine-acetate | hsa04924 | Renin secretion | 2.98E-03 | 4 | P22694, P07550, Q13370, P0DP23 | PRKACB, ADRB2, PDE3B, CALM1 | More | | Eslicarbazepine-acetate | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Eslicarbazepine-acetate | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Eslicarbazepine-acetate | hsa04932 | Non-alcoholic fatty liver disease | 4.86E-04 | 7 | O43521, O75460, P01584, P13073, P12074, O15239, O95298 | BCL2L11, ERN1, IL1B, COX4I1, COX6A1, NDUFA1, NDUFC2 | More | | Eslicarbazepine-acetate | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.11E-03 | 6 | P84022, Q13485, P10415, P42338, P49767, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PLCG1 | More | | Eslicarbazepine-acetate | hsa04940 | Type I diabetes mellitus | 4.18E-02 | 3 | P10747, P13765, P01375 | CD28, HLA-DOB, TNF | More | | Eslicarbazepine-acetate | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | Eslicarbazepine-acetate | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | | Eslicarbazepine-acetate | hsa04966 | Collecting duct acid secretion | 4.48E-02 | 1 | P00918 | CA2 | More | | Eslicarbazepine-acetate | hsa04970 | Salivary secretion | 3.57E-04 | 8 | P07550, Q08828, P51828, P22694, Q14643, P17252, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, ITPR1, PRKCA, CALM1, CAMP | More | | Eslicarbazepine-acetate | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Eslicarbazepine-acetate | hsa04975 | Fat digestion and absorption | 9.50E-04 | 1 | O14494 | PLPP1 | More | | Eslicarbazepine-acetate | hsa04976 | Bile secretion | 4.78E-02 | 3 | Q08828, P51828, Q14032 | ADCY1, ADCY7, BAAT | More | | Eslicarbazepine-acetate | hsa05010 | Alzheimer disease | 1.94E-03 | 16 | O15239, P13073, P12074, O15399, Q00535, Q9NZJ5, O75460, P0DP23, Q13564, P01584, O95197, Q71U36, P67870, P09603, P21796, P28070 | NDUFA1, COX4I1, COX6A1, GRIN2D, CDK5, EIF2AK3, ERN1, CALM1, APPBP1, IL1B, RTN3, TUBA1A, CSNK2B, CSF1, VDAC1, PSMB4 | More | | Eslicarbazepine-acetate | hsa05016 | Huntington disease | 2.46E-02 | 9 | O95298, P13073, P12074, P24928, P30876, P62487, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2A, POLR2B, POLR2G, ERN1, PSMB4, PSMD12 | More | | Eslicarbazepine-acetate | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Eslicarbazepine-acetate | hsa05032 | Morphine addiction | 1.34E-02 | 4 | P63218, P50151, Q07343, P43250 | GNG5, GNG10, PDE4B, GRK6 | More | | Eslicarbazepine-acetate | hsa05034 | Alcoholism | 4.86E-04 | 8 | P0DP24, Q96RR4, P0C0S5, Q93077, P62807, O60814, P84243, P68431 | CALM2, CAMKK2, H2AFZ, HIST1H2AC, HIST1H2BC, H2BC12, H3F3A, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Eslicarbazepine-acetate | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.96E-04 | 6 | Q16539, P09341, P19875, P19174, P25024, P25025 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Eslicarbazepine-acetate | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Eslicarbazepine-acetate | hsa05132 | Salmonella infection | 1.74E-04 | 14 | P51617, P25963, P01375, Q9UJU2, Q13546, Q13489, P10415, Q96A32, O60603, Q9BQS8, Q13561, O60282, Q13509, P68371 | IRAK1, NFKBIA, TNF, LEF1, RIPK1, BIRC3, BCL2, MYLPF, TLR2, FYCO1, DCTN2, KIF5C, TUBB3, TUBB2C | More | | Eslicarbazepine-acetate | hsa05133 | Pertussis | 2.35E-03 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Eslicarbazepine-acetate | hsa05134 | Legionellosis | 1.16E-04 | 7 | P01584, Q9NR31, P11215, P0DMV8, P11142, P09341, P19875 | IL1B, SAR1A, ITGAM, HSPA1A, HSPA8, CXCL1, CXCL2 | More | | Eslicarbazepine-acetate | hsa05140 | Leishmaniasis | 3.10E-06 | 13 | P13612, O75015, P14598, P23458, P13765, O60603, P25963, P01375, P01584, P49006, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, JAK1, HLA-DOB, TLR2, NFKBIA, TNF, IL1B, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | Eslicarbazepine-acetate | hsa05143 | African trypanosomiasis | 4.81E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Eslicarbazepine-acetate | hsa05144 | Malaria | 1.74E-03 | 6 | P60033, O60603, P01375, P35443, P01584, P26718 | CD81, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Eslicarbazepine-acetate | hsa05145 | Toxoplasmosis | 4.06E-03 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Eslicarbazepine-acetate | hsa05146 | Amoebiasis | 1.91E-06 | 14 | P01584, P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P30679, P22694, P12814, P08311 | IL1B, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Eslicarbazepine-acetate | hsa05150 | Staphylococcus aureus infection | 2.68E-03 | 8 | P0C0L4, P21730, P21462, O75015, P13765, Q16581, P13646, P49913 | C4A, C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, KRT13, CAMP | More | | Eslicarbazepine-acetate | hsa05152 | Tuberculosis | 8.50E-04 | 10 | Q13488, O75015, P48382, O60603, P01375, P10415, P13765, P49913, Q9UDY8, P51617 | TCIRG1, FCGR3B, RFX5, TLR2, TNF, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Eslicarbazepine-acetate | hsa05161 | Hepatitis B | 1.61E-03 | 10 | P17252, P14780, P25963, Q13485, P01375, P10415, P84022, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, SMAD4, TNF, BCL2, SMAD3, IRAK1, TLR2, STAT4 | More | | Eslicarbazepine-acetate | hsa05162 | Measles | 2.57E-03 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | | Eslicarbazepine-acetate | hsa05163 | Human cytomegalovirus infection | 2.68E-05 | 16 | P01375, Q14643, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, P61073, Q13651, P25025, Q16539, P04637, O00463 | TNF, ITPR1, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, CXCR4, IL10RA, CXCR2, MAPK14, TP53, TRAF5 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P49841 | GSK3B | Glycogen synthase kinase-3 beta | P01375 | TNF | Tumor necrosis factor | 0.732 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | -0.728 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P0DP23 | CALM1 | Calmodulin-1 | 0.822 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | P0DP23 | CALM1 | Calmodulin-1 | 0.762 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.727 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.727 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.84 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.829 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P51828 | ADCY7 | Adenylate cyclase type 7 | 0.834 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 1 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.847 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.78 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.778 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P01584 | IL1B | Interleukin-1 beta | 0.799 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | P01584 | IL1B | Interleukin-1 beta | 0.762 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | P61073 | CXCR4 | C-X-C chemokine receptor type 4 | 0.774 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.799 | P62942 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.769 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.889 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.861 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.78 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P04637 | TP53 | Cellular tumor antigen p53 | -0.823 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.734 |
| Eslicarbazepine-acetate | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Eslicarbazepine-acetate | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | | Eslicarbazepine-acetate | hsa05170 | Human immunodeficiency virus 1 infection | 2.58E-05 | 18 | Q02750, P62879, P16298, P01375, Q05397, P17252, O00463, Q14643, P51617, P25963, O60603, Q13315, O95067, P10415, Q13619, Q93034, Q9Y6Q5, P20333 | MAP2K1, GNB2, PPP3CB, TNF, PTK2, PRKCA, TRAF5, ITPR1, IRAK1, NFKBIA, TLR2, ATM, CCNB2, BCL2, CUL4A, CUL5, AP1M2, TNFRSF1B | More | | Eslicarbazepine-acetate | hsa05200 | Pathways in cancer | 1.31E-03 | 21 | Q13751, P42338, P08238, P42224, P19174, P43246, P84022, Q13485, Q13547, P14923, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P0DP23, P14784, P40189 | LAMB3, PIK3CB, HSP90AB1, STAT1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, CALM1, IL2RB, IL6ST | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | P29375 | JARID1A | Lysine-specific demethylase 5A | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P29375 | JARID1A | Lysine-specific demethylase 5A | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.711 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P29375 | JARID1A | Lysine-specific demethylase 5A | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.764 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P29375 | JARID1A | Lysine-specific demethylase 5A | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | P29375 | JARID1A | Lysine-specific demethylase 5A | P14923 | JUP | Junction plakoglobin | -0.735 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P29375 | JARID1A | Lysine-specific demethylase 5A | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.748 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | P29375 | JARID1A | Lysine-specific demethylase 5A | P0DP23 | CALM1 | Calmodulin-1 | 0.755 | P29375 | JARID1A | Lysine-specific demethylase 5A | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.768 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P29375 | JARID1A | Lysine-specific demethylase 5A | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.83 |
| Eslicarbazepine-acetate | hsa05202 | Transcriptional misregulation in cancer | 5.42E-08 | 21 | Q12778, Q15532, Q13315, P17844, P14780, P27930, P14923, Q16548, Q13489, Q13077, P08069, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | FOXO1, SS18, ATM, DDX5, MMP9, IL1R2, JUP, BCL2A1, BIRC3, TRAF1, IGF1R, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Eslicarbazepine-acetate | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Eslicarbazepine-acetate | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Eslicarbazepine-acetate | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P14780, P01375, P08069, P23588, Q13635, P22694 | MMP9, TNF, IGF1R, EIF4B, PTCH1, PRKACB | More | | Eslicarbazepine-acetate | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Eslicarbazepine-acetate | hsa05212 | Pancreatic cancer | 2.34E-04 | 5 | P42338, P42224, P84022, Q13485, O75293 | PIK3CB, STAT1, SMAD3, SMAD4, GADD45B | More | | Eslicarbazepine-acetate | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Eslicarbazepine-acetate | hsa05214 | Glioma | 1.88E-03 | 4 | P08069, P0DP23, P42338, O75293 | IGF1R, CALM1, PIK3CB, GADD45B | More | | Eslicarbazepine-acetate | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | | Eslicarbazepine-acetate | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | Eslicarbazepine-acetate | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Eslicarbazepine-acetate | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | | Eslicarbazepine-acetate | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Eslicarbazepine-acetate | hsa05220 | Chronic myeloid leukemia | 1.44E-03 | 6 | Q13547, Q13485, P25963, P84022, P42338, O75293 | HDAC1, SMAD4, NFKBIA, SMAD3, PIK3CB, GADD45B | More | | Eslicarbazepine-acetate | hsa05222 | Small cell lung cancer | 2.38E-03 | 6 | Q13489, P10415, P25963, Q13077, O00463, P24522 | BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A | More | | Eslicarbazepine-acetate | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | Eslicarbazepine-acetate | hsa05224 | Breast cancer | 1.24E-02 | 5 | P08069, P49841, Q92837, P04637, P24522 | IGF1R, GSK3B, FRAT1, TP53, GADD45A | More | | Eslicarbazepine-acetate | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | | Eslicarbazepine-acetate | hsa05226 | Gastric cancer | 4.33E-03 | 5 | Q02750, O15169, P84022, Q13485, P10415 | MAP2K1, AXIN1, SMAD3, SMAD4, BCL2 | More | | Eslicarbazepine-acetate | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.52E-05 | 13 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539, Q9HC35, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14, EML4, CD4 | More | | Eslicarbazepine-acetate | hsa05310 | Asthma | 2.14E-03 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Eslicarbazepine-acetate | hsa05321 | Inflammatory bowel disease | 1.21E-06 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | Eslicarbazepine-acetate | hsa05322 | Systemic lupus erythematosus | 2.54E-05 | 13 | O75015, P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, O60814, P68431, P05455 | FCGR3B, ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, SSB | More | | Eslicarbazepine-acetate | hsa05332 | Graft-versus-host disease | 2.07E-05 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Eslicarbazepine-acetate | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | Eslicarbazepine-acetate | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.48E-02 | 1 | P54284 | CACNB3 | More | | Eslicarbazepine-acetate | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | | Eslicarbazepine-acetate | hsa05415 | Diabetic cardiomyopathy | 4.23E-02 | 2 | O14521, P37173 | SDHD, TGFBR2 | More | | Eslicarbazepine-acetate | hsa05418 | Fluid shear stress and atherosclerosis | 1.56E-05 | 12 | Q16539, P42338, Q14145, P14598, P10599, P14780, P01375, P04637, P14778, P27930, P0DP23, P08238 | MAPK14, PIK3CB, KEAP1, NCF1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2, CALM1, HSP90AB1 | More | | |